Swiss multinational pharmaceutical corporation
Novartis AG is the second of Basel's two pharma giants, formed in 1996 through the merger of Ciba-Geigy and Sandoz - itself one of the largest corporate consolidations in Swiss history. The company generated roughly USD 50 billion in 2024 revenue from innovative medicines across oncology, cardiovascular, immunology, and neuroscience.
Novartis spun off its generics arm Sandoz in 2023 as a separately listed Swiss AG, refocusing the parent entirely on patent-protected medicines.
Unlike Roche, Novartis runs a full dual-listing: ordinary shares on SIX Swiss Exchange (NOVN) and sponsored American Depositary Shares on NYSE (NVS), with SEC-registered Form 20-F filings. This gives Novartis direct access to US institutional capital and is the typical structure for a Swiss AG that generates a plurality of revenue in US dollars.
Novartis employs roughly 78,000 people globally with major sites in Basel, East Hanover (NJ), Hyderabad, and Shanghai.
The listed entity is Novartis AG, a Swiss Aktiengesellschaft registered in Basel-Stadt. Share classes are unified (one-share-one-vote for registered shares), which is explicitly different from Roche's dual-class structure and closer to a US or UK-style listed company.
Novartis is the best worked example of a Swiss AG that chose a full NYSE dual listing rather than the cheaper OTC ADR route that Roche uses. The difference matters for founders and finance teams because it determines both the compliance burden and the investor base.
A full NYSE dual listing requires Novartis to prepare two complete sets of financial statements (Swiss Code of Obligations and IFRS for SIX, plus US GAAP reconciliation and SEC Form 20-F), to maintain two sets of disclosure controls (FINMA/SIX ad-hoc disclosure plus SEC Regulation FD), and to pay two sets of listing fees and auditor attestations. The incremental cost runs in the tens of millions of dollars annually.
In exchange, Novartis gets pricing on the deepest equity market in the world, a broader US mutual fund shareholder base, and the ability to use registered US shares as M&A currency in dollar-denominated transactions.
This is exactly the trade-off the Sandoz spinoff was designed to test in 2023. Sandoz now lists on SIX only (plus an OTC ADR), explicitly choosing the cheaper Roche-style path. Novartis retained the full NYSE listing.
Over the next five years, the relative multiples at which Novartis and Sandoz trade will reveal whether the NYSE premium is worth the compliance cost - a natural experiment every Swiss scaleup CFO should monitor.
Cantonally, Novartis is also Basel-Stadt. Combined federal-plus-cantonal corporate income tax is roughly 13-14%, patent-box benefits under Swiss tax reform (TRAF, 2020) reduce the effective rate on qualifying patent income to as low as 9-11% depending on canton, and the canton provides dense pharma talent and proximity to Swissmedic.
For a pharma or biotech founder, Basel-Stadt and Zug are the two serious choices; Zurich is a distant third for life sciences specifically.
Both are Basel pharma AGs, but Novartis runs a one-share-one-vote structure with a full NYSE dual listing, while Roche runs a family-controlled dual-class structure with only an OTC ADR in the US. Novartis is operationally larger by headcount; Roche has a higher revenue-per-employee in recent years.
To focus the parent on high-margin patent-protected medicines and give the generics business its own cost-of-capital. Sandoz listed on SIX in October 2023 as an independent Swiss AG.
Yes, via sponsored ADRs with SEC Form 20-F registration. Novartis, UBS, ABB, and Logitech all do this. The incremental compliance cost is substantial but opens direct access to US institutional capital.
Introduced in 2020 under the TRAF reform, the patent box reduces cantonal tax on income from qualifying patents. Effective rates drop to roughly 9-11% depending on canton. Critical for pharma, biotech, and deep-tech Swiss AGs.
